Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug RC278 targets Hard-to-Treat solid tumors in early trial

NCT ID NCT07105215

Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good overall health are being recruited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 312 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily participate in this study, sign the informed consent form, and be able to adhere to the study protocol; 2. Age between 18 and 75 years (including 18 and 75 years); 3. ECOG PS score of 0 or 1; 4. Expected survival ≥12 weeks; 5. According to RECIST v1.1 criteria, based on imaging examinations, there is at least one measurable target lesion; 6. Sufficient bone marrow, liver, kidney, and blood clotting function Exclusion Criteria: 1. Pregnant, breastfeeding, or intending to become pregnant subjects. 2. Subjects with brain metastases. 3. Subjects with unresolved toxicities from prior anti-tumor therapy not recovered to NCI-CTCAE v5.0 Grade 1. 4. Subjects with known hypersensitivity or delayed allergic reactions to any component of the investigational drug or similar drugs. 5. Subjects with acute, chronic, or symptomatic infections. 6. Subjects with uncontrolled cardiovascular diseases. 7. Subjects with confirmed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severely impaired pulmonary function, or other pulmonary diseases. 8. Subjects with a history of cirrhosis (Child-Pugh B or C class). 9. Subjects with active inflammatory bowel disease. 10. Subjects with uncontrolled diabetes (HbA1c ≥ 10%). 11. Subjects who experienced arterial/venous thromboembolic events, deep vein thrombosis, pulmonary embolism, or stroke within 6 months prior to the first dose. 12. Subjects with pericardial effusion or cardiac tamponade, or third-space fluid accumulation, which, in the investigator's judgment, cannot be controlled or stabilized by drainage or other methods. 13. Subjects with active autoimmune diseases requiring systemic treatment within the past 2 years. 14. Subjects with a history of other invasive malignancies within 5 years prior to the first dose, or evidence of residual disease from a previously diagnosed malignancy. 15. Subjects with a history of other acquired or congenital immunodeficiency diseases or organ transplantation. 16. Subjects with a history or current diagnosis of uncontrolled psychiatric disorders. 17. Subjects with poor adherence, who are unlikely to comply with the trial procedures. 18. Subjects with any other diseases, metabolic abnormalities, physical examination abnormalities, or laboratory abnormalities, which, in the investigator's judgment, raise suspicion of an underlying condition making the subject unsuitable for the investigational drug, or which may affect the interpretation of the study results, or place the subject at high risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced unresectable or metastatic malignant solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    39 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anyang Cancer Hospital

    RECRUITING

    Luoyan, Henan, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, China

  • Cancer Hospital of Shandong First Medical University

    RECRUITING

    Jinan, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, China

  • Fujian Medical University Union Hospital

    RECRUITING

    Fuzhou, Fujian, China

  • Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute

    RECRUITING

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    RECRUITING

    Nanjing, Jiangsu, China

  • Jinan Central Hospital

    RECRUITING

    Jinan, China

  • Liaoning Cancer Hospital & Institute

    RECRUITING

    Shenyang, Liaoning, China

  • Nanyang Second General Hospital

    RECRUITING

    Nanyang, Henan, China

  • Shanxi Cancer Hospital

    RECRUITING

    Taiyuan, China

  • Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, China

  • Taizhou Hospital of Zhejiang Province

    RECRUITING

    Taizhou, Zhejiang, China

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, Jiangsu, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    RECRUITING

    Luoyang, Henan, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, China

  • The First Affiliated Hospital of Xinxiang Medical University

    RECRUITING

    Xinxiang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

  • The First Affiliated Hospital, Zhejiang University School Of Medicine

    RECRUITING

    Hangzhou, China

  • The Second Affiliated Hospital of Guilin Medical University

    RECRUITING

    Guilin, Guangxi, China

  • The first Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, China

  • Tongji Hospital, Tongji Medical College of HUST, China

    RECRUITING

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

    RECRUITING

    Wuhan, Hu'Nan, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

  • Xuzhou Central Hospital

    RECRUITING

    Xuzhou, Jiangsu, China

  • Yunnan Tumor Hospital

    RECRUITING

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • Zhongshan Hospital, Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.